Summit Therapeutics (SMMT) Other Working Capital Changes (2019 - 2026)

Summit Therapeutics has reported Other Working Capital Changes for 8 years, with the latest figure at -$33000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Working Capital Changes rose 98.22% year-over-year to -$33000.0; the trailing twelve-month figure through Mar 2026 stood at $6.7 million (up 210.43% YoY), and the FY2025 full-year result was $4.9 million, up 297.37% from the prior year.
• Other Working Capital Changes for Q1 2026 stood at -$33000.0, down from $8.5 million in the prior quarter.
• The five-year high for Other Working Capital Changes was $8.5 million in Q4 2025, with the low at -$7.2 million in Q4 2023.
• Historically, Other Working Capital Changes has averaged -$73000.0 across 5 years, with a median of -$297000.0 in 2022.
• The largest YoY upside for Other Working Capital Changes was 664.73% in 2025 against a maximum downside of 4413.95% in 2025.
• Summit Therapeutics' Other Working Capital Changes stood at $5.0 million in 2022, then slumped by 243.17% to -$7.2 million in 2023, then surged by 78.92% to -$1.5 million in 2024, then surged by 664.73% to $8.5 million in 2025, then tumbled by 100.39% to -$33000.0 in 2026.
• The last three Other Working Capital Changes figures came in at -$33000.0 (Q1 2026), $8.5 million (Q4 2025), and -$3.7 million (Q3 2025), per Business Quant data.